According to Gram Research analysis of multiple studies, SGLT2 inhibitor medications (gliflozins) appear safe for bone health in chronic kidney disease patients, with most research showing no significant increase in fracture risk. While early concerns about bone fractures were raised in a couple of studies, these findings were not confirmed by subsequent research, and one study even suggested these medications may help improve bone mineral markers in kidney disease patients.
A Gram Research analysis of multiple studies examined whether a popular class of kidney disease medications called SGLT2 inhibitors (gliflozins) affects bone health and fracture risk. Researchers reviewed randomized controlled trials and observational studies to understand if these drugs, which help protect kidneys in patients with chronic kidney disease, might weaken bones or increase fracture risk. The good news: most studies found these medications appear safe for bones, though some early concerns about fractures were raised in a few studies. However, scientists note that more long-term research is needed, especially in patients with advanced kidney disease.
Key Statistics
A systematic review of randomized controlled trials and cohort studies found that while one early trial reported increased fracture risk with SGLT2 inhibitors in kidney disease patients, this finding was not replicated in most subsequent studies, which generally showed non-significant differences in bone outcomes.
One study included in the systematic review reported that SGLT2 inhibitors may favorably modulate kidney-related bone disease markers, showing reduced risk of hyperphosphatemia, hypocalcemia, elevated parathyroid hormone, and vitamin D deficiency in chronic kidney disease patients.
A 2026 systematic review in the Journal of Nephrology examined bone safety of SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) in chronic kidney disease patients, finding mostly reassuring skeletal safety profiles, though evidence in moderate-to-advanced kidney disease remains limited.
The Quick Take
- What they studied: Whether SGLT2 inhibitor medications (gliflozins) used to treat chronic kidney disease affect bone strength, fracture risk, and bone mineral health
- Who participated: Multiple studies involving patients with chronic kidney disease, primarily those in early stages of the disease, with most studies originally designed for people with type 2 diabetes
- Key finding: Most studies showed these kidney medications do not significantly increase fracture or bone problems, though a couple of early studies raised concerns that weren’t confirmed by later research
- What it means for you: If you take SGLT2 inhibitors for kidney disease, current evidence suggests these medications appear safe for your bones. However, discuss bone health monitoring with your doctor, especially if you have advanced kidney disease, since research in that group is still limited
The Research Details
Researchers conducted a systematic review, which means they searched medical databases for all published studies about SGLT2 inhibitors and bone health in kidney disease patients. They included both randomized controlled trials (where patients are randomly assigned to receive the medication or a placebo) and cohort studies (where researchers follow groups of patients over time). The team extracted information about study design, patient characteristics, kidney function levels, and any bone-related outcomes like fractures, falls, or changes in bone mineral markers.
The researchers carefully evaluated the quality and potential bias of each study included in their analysis. They looked at whether studies properly measured bone outcomes and whether results were consistent across different studies. This approach helps identify patterns in the evidence and spot areas where more research is needed.
This systematic review approach is valuable because it combines evidence from many studies rather than relying on a single trial, giving a more complete picture of medication safety. However, the strength of conclusions depends on the quality and consistency of the individual studies reviewed.
Chronic kidney disease patients often face multiple health challenges, including bone problems. SGLT2 inhibitors are important medications that protect kidney function, but doctors need to know if they affect bone health. This review helps clarify whether the benefits of these medications outweigh any bone-related risks, which is crucial for treatment decisions.
The review examined multiple study types, which strengthens confidence in the findings. However, the evidence has important limitations: most studies were originally designed to study diabetes, not kidney disease specifically; most participants had early-stage kidney disease; bone outcomes were measured inconsistently across studies; and very few studies specifically examined advanced kidney disease patients. These factors mean the conclusions are most reliable for early-stage kidney disease but less certain for more advanced cases.
What the Results Show
The systematic review found that most studies showed SGLT2 inhibitors do not significantly increase fracture risk or bone problems in chronic kidney disease patients. While one randomized controlled trial and one cohort study reported increased fracture and amputation risk, these concerning findings were not repeated in other studies. Most other randomized trials and cohort studies showed no significant differences in bone outcomes between patients taking SGLT2 inhibitors and those not taking them.
One particularly interesting finding suggests that SGLT2 inhibitors may actually help with bone mineral disease—a specific bone problem common in kidney disease patients. This study reported that patients taking these medications had lower rates of high phosphate levels, low calcium levels, high parathyroid hormone, and low vitamin D, all markers of kidney-related bone disease.
The medications studied most frequently in the research were empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin. Overall, the evidence suggests these drugs have a reassuring safety profile for bones in kidney disease patients, though researchers emphasize that more consistent measurement and reporting of bone outcomes across studies would strengthen these conclusions.
The review identified important variations in how different studies measured bone health. Some studies looked at fracture rates, others at bone mineral density, and still others at biochemical markers of bone metabolism. This inconsistency makes it harder to compare results across studies and draw firm conclusions. Additionally, the research revealed that most evidence comes from studies in patients with early-stage kidney disease, with much less data available for those with moderate-to-advanced disease.
Initial concerns about SGLT2 inhibitors and bone fractures emerged from early studies, particularly in diabetes research. This systematic review shows that those early concerns have not been consistently supported by subsequent research. The pattern of findings suggests that initial safety signals may have been false alarms or specific to certain patient populations. However, the review notes that evidence in moderate-to-advanced kidney disease remains limited compared to early-stage disease.
Several important limitations affect how much we can trust these conclusions. First, most studies were designed primarily for diabetes patients, not kidney disease patients specifically. Second, the reporting of bone outcomes was inconsistent—different studies measured different things in different ways. Third, most participants had early-stage kidney disease, so we know less about safety in advanced kidney disease. Fourth, the sample sizes and study designs varied considerably. Finally, the review did not include long-term prospectively defined bone outcomes, meaning we lack data on fracture prevention over many years of treatment.
The Bottom Line
Current evidence suggests SGLT2 inhibitors appear safe for bone health in chronic kidney disease patients, particularly those with early-stage disease (moderate confidence). These medications should not be avoided based on bone health concerns alone. However, patients with advanced kidney disease should discuss bone monitoring with their nephrologist, as evidence in this group is still developing (lower confidence). Continue regular bone health practices including adequate calcium and vitamin D intake, weight-bearing exercise, and fall prevention.
This research is most relevant for people with early-to-moderate chronic kidney disease considering or currently taking SGLT2 inhibitors. It’s particularly important for those worried about fracture risk or those with existing bone problems. People with advanced kidney disease should discuss these findings with their kidney specialist, as evidence specific to their situation is still limited. Healthcare providers treating kidney disease patients should find this reassuring regarding medication safety.
Bone health changes typically develop over months to years. If you’re starting an SGLT2 inhibitor, you won’t see immediate effects on bone strength. Bone mineral density changes can be detected with imaging after 1-2 years. Fracture risk reduction, if it occurs, would likely take several years to become apparent. Regular monitoring through clinical follow-up is more important than expecting rapid changes.
Frequently Asked Questions
Do SGLT2 inhibitors cause bone fractures in kidney disease patients?
Most research shows SGLT2 inhibitors do not significantly increase fracture risk in kidney disease patients. While a couple of early studies raised concerns, subsequent research did not confirm these findings. Current evidence suggests these medications have a reassuring safety profile for bones.
Are gliflozin medications safe for people with chronic kidney disease?
Yes, SGLT2 inhibitors (gliflozins) appear safe for bone health in chronic kidney disease patients, particularly those with early-stage disease. One study even suggests they may help improve bone mineral markers. However, more research is needed in advanced kidney disease.
What should I do to protect my bones while taking SGLT2 inhibitors?
Maintain adequate calcium and vitamin D intake through diet or supplements, engage in weight-bearing exercise 3-4 times weekly, avoid falls through home safety measures, and have regular check-ups with your doctor to monitor bone health markers if recommended.
Do SGLT2 inhibitors affect calcium and vitamin D levels in kidney disease?
One study found that SGLT2 inhibitors may actually help prevent low calcium and vitamin D levels in kidney disease patients. However, more research is needed to confirm this finding across different patient groups and medication types.
Is there enough research on bone safety of these kidney medications?
Most evidence comes from early-stage kidney disease patients, with limited data for advanced disease. Researchers call for more long-term studies with consistent bone outcome measurements to fully confirm safety across all kidney disease stages.
Want to Apply This Research?
- Log your SGLT2 inhibitor medication adherence daily and track any falls, injuries, or bone pain weekly. Record calcium and vitamin D intake through food or supplements to ensure adequate nutrition for bone health.
- Set reminders for weight-bearing exercise (walking, light strength training) 3-4 times weekly, which supports bone health. Track dietary sources of calcium and vitamin D, aiming for recommended daily amounts. Document any new joint or bone symptoms to discuss with your doctor.
- Maintain a quarterly summary of bone health markers if your doctor orders them (calcium, phosphate, vitamin D, parathyroid hormone levels). Note any changes in balance, falls, or bone-related symptoms. Schedule annual check-ins with your healthcare provider to review bone health status and medication effectiveness.
This article summarizes research findings and should not replace professional medical advice. SGLT2 inhibitors are prescription medications that should only be used under doctor supervision. If you have chronic kidney disease and are considering or currently taking these medications, discuss bone health concerns, monitoring needs, and any symptoms with your nephrologist or primary care physician. This is especially important if you have advanced kidney disease, existing bone problems, or a history of fractures. Individual responses to medication vary, and your doctor can assess your specific situation and risk factors.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.